Skip to content


Cinqair, Cinqaero (reslizumab) is an antibody pharmaceutical. Reslizumab was first approved as Cinqair on 2016-03-23. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma. The pharmaceutical is active against interleukin-5.
Trade Name Cinqaero
Common Name Reslizumab
Indication asthma
Drug Class Monoclonal antibodies: humanized, immunomodulating
Get full access now